T1	p 63 123	asthma due to house dust mite Dermatophagoides pteronyssinus
T2	p 168 181	immunotherapy
T3	p 284 318	extract of house dust mite ( HDM )
T4	p 387 434	10 patients with asthma due to HDM were studied
T5	p 458 474	patients ( Group
T6	p 533 545	5 patients (
T7	p 882 892	2 patients
T8	p 960 970	with HDM .
T9	p 1050 1094	and ultrasonically nebulized distilled water
T10	p 1427 1440	asthma due to
T11	i 6 25	Local immunotherapy
T12	i 29 39	inhalation
T13	i 43 59	a powder extract
T14	i 83 125	dust mite Dermatophagoides pteronyssinus :
T15	i 157 183	parenteral immunotherapy .
T16	i 231 257	local immunotherapy ( LI )
T17	i 261 271	inhalation
T18	i 275 310	a powder extract of house dust mite
T19	i 340 371	parenteral immunotherapy ( PI )
T20	i 375 384	injection
T21	i 477 530	) underwent LI and subcutaneous injections of placebo
T22	i 552 553	B
T23	i 556 572	underwent PI and
T24	i 587 594	lactose
T25	i 630 640	inhalation
T26	i 657 670	premedication
T27	i 676 697	disodium cromoglycate
T28	i 717 718	.
T29	i 1037 1049	methacholine
T30	i 1054 1103	ultrasonically nebulized distilled water ( UNDW )
T31	i 1207 1208	.
T32	o 198 210	efficacy and
T33	o 215 227	tolerability
T34	o 370 371	)
T35	o 573 594	inhalation of lactose
T36	o 705 706	)
T37	o 756 774	symptoms score and
T38	o 778 826	peak expiratory flow ( PEF ) -derived parameters
T39	o 902 916	late component
T40	o 924 942	bronchial response
T41	o 1019 1036	responsiveness to
T42	o 1111 1130	immunologic humoral
T43	o 1135 1154	cellular parameters
T44	o 1158 1168	peripheral
T45	o 1212 1217	local
T46	o 1228 1245	adverse reactions
T47	o 1278 1299	systemic side effects
T48	o 1371 1373	PI
T49	o 1572 1593	systemic side effects